HRP20020369A2 - Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties - Google Patents

Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties Download PDF

Info

Publication number
HRP20020369A2
HRP20020369A2 HR20020369A HRP20020369A HRP20020369A2 HR P20020369 A2 HRP20020369 A2 HR P20020369A2 HR 20020369 A HR20020369 A HR 20020369A HR P20020369 A HRP20020369 A HR P20020369A HR P20020369 A2 HRP20020369 A2 HR P20020369A2
Authority
HR
Croatia
Prior art keywords
group
glyoxylamide
residue
groups
alkyl
Prior art date
Application number
HR20020369A
Other languages
English (en)
Croatian (hr)
Inventor
Bernd Nickel
Thomas Klenner
Gerald Bacher
Thomas Beckers
Peter Emig
Juergen Engel
Erik Bruyneel
Guenter Kamp
Kirsten Peters
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/de
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of HRP20020369A2 publication Critical patent/HRP20020369A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
HR20020369A 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties HRP20020369A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946301A DE19946301A1 (de) 1998-04-02 1999-09-28 Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
PCT/EP2000/009390 WO2001022954A2 (de) 1999-09-28 2000-09-26 Indolyl-3-glyoxylsäurederivate als antitumormittel

Publications (1)

Publication Number Publication Date
HRP20020369A2 true HRP20020369A2 (en) 2004-12-31

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020369A HRP20020369A2 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties

Country Status (32)

Country Link
EP (1) EP1218006B1 (cs)
JP (1) JP2003510274A (cs)
KR (1) KR100759242B1 (cs)
CN (1) CN1301712C (cs)
AR (1) AR025885A1 (cs)
AT (1) ATE459356T1 (cs)
AU (1) AU783436B2 (cs)
BG (1) BG106639A (cs)
BR (1) BR0014378A (cs)
CA (1) CA2386069C (cs)
CZ (1) CZ303246B6 (cs)
DE (1) DE50015879D1 (cs)
DZ (1) DZ3196A1 (cs)
EE (1) EE200200169A (cs)
ES (1) ES2342042T3 (cs)
GE (1) GEP20043250B (cs)
HK (1) HK1048941B (cs)
HR (1) HRP20020369A2 (cs)
HU (1) HUP0202788A3 (cs)
IL (2) IL148670A0 (cs)
IS (1) IS6319A (cs)
MX (1) MXPA02002824A (cs)
NO (1) NO322614B1 (cs)
NZ (1) NZ517988A (cs)
PL (1) PL199576B1 (cs)
RS (1) RS51302B (cs)
RU (1) RU2282444C2 (cs)
SK (1) SK287533B6 (cs)
TW (1) TWI269654B (cs)
UA (1) UA75872C2 (cs)
WO (1) WO2001022954A2 (cs)
ZA (1) ZA200202556B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
RU2327696C2 (ru) * 2003-06-05 2008-06-27 Центарис Гмбх Производные индола, обладающие индуцирующим апоптоз эффектом (варианты), фармацевтическая композиция на их основе
EP1595878A1 (de) * 2004-05-15 2005-11-16 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
ES2777924T3 (es) * 2004-05-23 2020-08-06 Hmi Medical Innovations Llc Moduladores de teramuteína
JP2008519036A (ja) * 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20080241274A1 (en) * 2006-11-28 2008-10-02 Ziopharm Oncology, Inc. Indibulin therapy
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (zh) * 2017-06-23 2022-04-22 首都医科大学 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成，活性和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
RU2047603C1 (ru) * 1991-12-09 1995-11-10 Матвей Абрамович Рехтер 1-алкил-2-ацилиндолы и способы их получения
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
WO1994008581A1 (en) * 1992-10-20 1994-04-28 Toray Industries, Inc. Eosinophil infiltration inhibitor
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU6523598A (en) 1997-04-08 1998-10-30 Banyu Pharmaceutical Co., Ltd. Cancerous metastasis-associated gene
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
WO1999046237A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TR200003130T2 (tr) * 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
JP2000239252A (ja) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Also Published As

Publication number Publication date
NO322614B1 (no) 2006-11-06
PL364811A1 (en) 2004-12-13
CZ303246B6 (cs) 2012-06-20
ZA200202556B (en) 2003-08-27
JP2003510274A (ja) 2003-03-18
BG106639A (bg) 2002-12-29
AU7782900A (en) 2001-04-30
HUP0202788A2 (hu) 2003-01-28
KR20030019295A (ko) 2003-03-06
CZ20021005A3 (cs) 2004-01-14
UA75872C2 (en) 2006-06-15
TWI269654B (en) 2007-01-01
AR025885A1 (es) 2002-12-18
BR0014378A (pt) 2003-07-29
RS51302B (sr) 2010-12-31
NO20021367L (no) 2002-05-22
IL148670A0 (en) 2002-09-12
SK4072002A3 (en) 2003-11-04
WO2001022954A2 (de) 2001-04-05
NZ517988A (en) 2004-10-29
AU783436B2 (en) 2005-10-27
EE200200169A (et) 2003-04-15
PL199576B1 (pl) 2008-10-31
HK1048941B (zh) 2007-09-21
DZ3196A1 (fr) 2001-04-05
CN1301712C (zh) 2007-02-28
KR100759242B1 (ko) 2007-09-18
HK1048941A1 (en) 2003-04-25
CA2386069A1 (en) 2001-04-05
IL148670A (en) 2009-09-01
ATE459356T1 (de) 2010-03-15
DE50015879D1 (de) 2010-04-15
HUP0202788A3 (en) 2003-02-28
EP1218006A2 (de) 2002-07-03
GEP20043250B (en) 2004-06-25
CA2386069C (en) 2012-08-14
IS6319A (is) 2002-03-21
MXPA02002824A (es) 2003-07-21
WO2001022954A3 (de) 2002-03-28
NO20021367D0 (no) 2002-03-19
EP1218006B1 (de) 2010-03-03
CN1376064A (zh) 2002-10-23
RU2282444C2 (ru) 2006-08-27
SK287533B6 (sk) 2011-01-04
ES2342042T3 (es) 2010-07-01
YU22702A (sh) 2004-12-31

Similar Documents

Publication Publication Date Title
HRP20020369A2 (en) Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
US20080057124A1 (en) Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
JP2010535508A5 (cs)
RU2002111866A (ru) Производные N-замещенного индол-3-глиоксиламида - противоопухолевое лекарственное средство и средство, подавляющее ангиогенез (варианты), фармацевтическая композиция и противоопухолевое лекарственное средство (варианты)
BR112013028095B1 (pt) Uso de inibidores de csf-1r para o tratamento de tumores cerebrais
CA2586228A1 (en) Histone deacetylase inhibitors and methods of use
KR20220124739A (ko) 암의 치료를 위한 병용 요법
CA2559282A1 (en) Methods for the treatment of synucleinopathies
CN103619331A (zh) 抗癌治疗剂
AU2009240908B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
JP2010511041A5 (cs)
US10335427B2 (en) Tumor prevention and treatment drug and applications thereof
US10118921B2 (en) Diarylmethylidene piperidine derivatives and their use as delta opoid receptor agnists
Scheepe et al. Endothelin‐A‐receptor antagonist LU 302146 inhibits electrostimulation‐induced bladder contractions in vivo
JP2004514683A (ja) レバミゾール及び５−フルオロウラシルの同時投与法

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060913

Year of fee payment: 7

PPPP Transfer of rights

Owner name: ZIOPHARM ONCOLOGY, INC., US

OBST Application withdrawn